NASDAQ:SXTP 60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis $1.39 -0.04 (-2.80%) Closing price 06/9/2026 04:00 PM EasternExtended Trading$1.41 +0.02 (+1.44%) As of 07:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About 60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SXTP alerts:Sign Up Key Stats Today's Range$1.37▼$1.5050-Day Range$1.39▼$2.2252-Week Range$1.29▼$11.84Volume74,356 shsAverage Volume52,462 shsMarket Capitalization$3.70 millionP/E RatioN/ADividend YieldN/APrice Target$13.85Consensus RatingHold Company Overview 60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. Read More 60 Degrees Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks74th Percentile Overall ScoreSXTP MarketRank™: 60 Degrees Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus Rating60 Degrees Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside Potential60 Degrees Pharmaceuticals has a consensus price target of $13.85, representing about 896.4% upside from its current price of $1.39.Amount of Analyst Coverage60 Degrees Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about 60 Degrees Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 60 Degrees Pharmaceuticals are expected to grow in the coming year, from ($3.30) to ($2.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 60 Degrees Pharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 60 Degrees Pharmaceuticals is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about 60 Degrees Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.99% of the float of 60 Degrees Pharmaceuticals has been sold short.Short Interest Ratio / Days to Cover60 Degrees Pharmaceuticals has a short interest ratio ("days to cover") of 1.99, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 60 Degrees Pharmaceuticals has recently decreased by 7.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield60 Degrees Pharmaceuticals does not currently pay a dividend.Dividend Growth60 Degrees Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News Sentiment60 Degrees Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for 60 Degrees Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest5 people have searched for SXTP on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows4 people have added 60 Degrees Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, 60 Degrees Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.69% of the stock of 60 Degrees Pharmaceuticals is held by insiders.Percentage Held by Institutions7.96% of the stock of 60 Degrees Pharmaceuticals is held by institutions.Read more about 60 Degrees Pharmaceuticals' insider trading history. Receive SXTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 60 Degrees Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SXTP Stock News Headlines60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with BabesiosisMay 26, 2026 | globenewswire.comHC Wainwright & Co. downgrades 60 Degrees Pharmaceuticals (SXTP)May 21, 2026 | msn.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.June 10 at 1:00 AM | Behind the Markets (Ad)60 Degrees Pharmaceuticals Announces First Quarter 2026 ResultsMay 15, 2026 | globenewswire.com60 Degrees Pharmaceuticals (SXTP) price target decreased by 19.89% to 14.38April 30, 2026 | msn.com60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel WebsiteApril 15, 2026 | markets.businessinsider.com60 Degrees Pharmaceuticals Announces 2025 Annual ResultsMarch 31, 2026 | globenewswire.com60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut ExtractMarch 18, 2026 | globenewswire.comSee More Headlines SXTP Stock Analysis - Frequently Asked Questions How have SXTP shares performed this year? 60 Degrees Pharmaceuticals' stock was trading at $2.0332 at the start of the year. Since then, SXTP shares have decreased by 31.6% and is now trading at $1.39. How were 60 Degrees Pharmaceuticals' earnings last quarter? 60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) issued its earnings results on Friday, May, 15th. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.52. The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.44 million. When did 60 Degrees Pharmaceuticals' stock split? Shares of 60 Degrees Pharmaceuticals reverse split before market open on Tuesday, January 20th 2026.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 19th 2026. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. When did 60 Degrees Pharmaceuticals IPO? 60 Degrees Pharmaceuticals (SXTP) raised $7 million in an IPO on Wednesday, July 12th 2023. The company issued 1,400,000 shares at $5.30 per share. WallachBeth Capital LLC acted as the underwriter for the IPO. How do I buy shares of 60 Degrees Pharmaceuticals? Shares of SXTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 60 Degrees Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that 60 Degrees Pharmaceuticals investors own include Recursion Pharmaceuticals (RXRX), Editas Medicine (EDIT), Pacific Biosciences of California (PACB), Tilray Brands (TLRY), Akanda (AKAN), Better Therapeutics (BTTX) and Honeywell International (HON). Company Calendar Last Earnings5/15/2026Today6/09/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 SXTP's financial health is in the Yellow zone, according to TradeSmith. SXTP has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SXTP CIK1946563 Web60degreespharma.com Phone202-327-5422FaxN/AEmployees3Year Founded2010Price Target and Rating Average Price Target for 60 Degrees Pharmaceuticals$13.85 High Price Target$24.00 Low Price Target$3.70 Potential Upside/Downside+896.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($8.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.36 million Net Margins-574.91% Pretax Margin-576.50% Return on EquityN/A Return on Assets-131.48% Debt Debt-to-Equity RatioN/A Current Ratio3.34 Quick Ratio2.85 Sales & Book Value Annual Sales$1.41 million Price / Sales2.62 Cash FlowN/A Price / Cash FlowN/A Book Value($5.85) per share Price / Book-0.24Miscellaneous Outstanding Shares2,660,000Free Float2,614,000Market Cap$3.70 million OptionableNot Optionable Beta2.65 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:SXTP) was last updated on 6/10/2026 by MarketBeat.com Staff. From Our PartnersHe Called NVIDIA at $1.10 – Now He Says, “SELL”The analyst who called NVIDIA at $1.10 now says sell. According to Alexander Green, Chief Investment Strategis...The Oxford Club | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTesla. SolarCity. Twitter. This $4 stock is next.Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredThis IPO Could Make SpaceX Look Small (Read before June 16)A red-hot AI startup just filed to go public - already valued at nearly $1 trillion. Wall Street veteran Marc ...Chaikin Analytics | SponsoredThe part that convinced me Joel is legitMost trading gurus cite big win rates but won't let you verify them. Joel Peterson is different - his trade pl...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SXTP Stock Alerts